Randomised, triple-masked, crossover Phase I study (n=20) comparing oral psilocin (17.5 mg), sublingual psilocin (2.18–4.36 mg), and oral psilocybin (25 mg) in healthy adults with preparatory and integration sessions.
This is a randomized, triple-masked, within-subject crossover study in 20 healthy adults comparing physiological and psychological effects of oral psilocin, sublingual psilocin, and oral psilocybin across multiple supervised dosing sessions.
Participants undergo baseline assessments, preparatory visits with trained facilitators, supervised dosing with clinician safety monitoring, and post-session integration; procedures may be repeated up to three additional times per participant.
Within-subject crossover: oral psilocin, sublingual psilocin, and oral psilocybin in randomized order; possible additional sublingual session for some participants.
Oral psilocin 17.5 mg with psychological support and monitoring.
Oral psilocybin 25 mg with psychological support and monitoring.
Sublingual psilocin range 2.18–4.36 mg (upper value shown); some participants may receive a second sublingual session.